Adverse effects of antipsychotic drugs

Video
Introduction to this topic

Presenter:
Professor David Owens
Professor of Clinical Psychiatry, University of Edinburgh

Updated: Wednesday, 27th April 2011
Last Checked: Wednesday, 18th October 2017 Current

Supporting Files

Supporting files for this topic are available if you have a current CPD subscription.

In addition to their therapeutic effect mediated by region-specific antagonism of dopamine D2 receptors (the “target” action), antipsychotic drugs generally have additional, often multiple, “non-target” actions. All actions not directly mediating the therapeutic action are side-effects, and many of these are clinically adverse. After introducing these general principles, this topic illustrates them using three important areas. First, a range of cardiovascular actions are described, including QTc prolongation and other potential mechanisms of increased mortality, as well as increased risk of cerebrovascular events. The second describes the metabolic syndrome of weight gain, atherogenic dyslipidaemias, hypertension and impaired glucose tolerance. Third, adverse motor (“extrapyramidal”) effects of D2 receptor antagonism in non-target regions are described, with a particular emphasis on parkinsonism.

Back to Schizophrenia

NB you need to be logged in and your subscription must be up to date in order to view the presentations below

Sections in this Topic

Play the video for Section

Adverse effects of antipsychotics - Introduction

Duration: 01m 50s
No. of slides: 7 - View Slide List


Play the video for Section

Cardiovascular Non-target Actions

Duration: 13m 29s
No. of slides: 24 - View Slide List


Play the video for Section

Metabolic effects

Duration: 04m 21s
No. of slides: 7 - View Slide List


Play the video for Section

Extrapyramidal side-effects (EPSE)

Duration: 05m 22s
No. of slides: 13 - View Slide List